Stocks Recover Losses from Iran
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 hours ago
0mins
Should l Buy COO?
Source: Barron's
- Market Reaction: The S&P 500 index has returned to its previous levels prior to the attacks in Iran.
- Impact of Events: The market's recovery indicates resilience despite geopolitical tensions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COO
Wall Street analysts forecast COO stock price to rise
12 Analyst Rating
7 Buy
4 Hold
1 Sell
Moderate Buy
Current: 83.370
Low
73.00
Averages
90.33
High
100.00
Current: 83.370
Low
73.00
Averages
90.33
High
100.00
About COO
The Cooper Companies, Inc. is a global medical device company. The Company operates in two business units: CooperVision and CooperSurgical. CooperVision segment is involved in the contact lens industry. CooperSurgical segment is involved in the fertility and women's health care market through its diversified portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. CooperVision’s products include MyDay daily disposable, MyDay daily disposable toric, MyDay Energys, MyDay multifocal, Biofinity & Biofinity XR, Biofinity Energys. CooperSurgical’s portfolio includes INSORB, Lone Star, and the Doppler Blood Flow Monitor. It also offers a suite of single-use cordless surgical retractors with an integrated multi-light-emitting diode (LED) light source and dual smoke evacuation channels, and single-use surgical suction devices with an integrated, cordless radial LED light source.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
The Cooper Companies to Announce Q1 Earnings on March 5
- Earnings Announcement: The Cooper Companies (COO) is set to release its Q1 2023 earnings on March 5 after market close, with consensus EPS estimates at $1.03, reflecting a 12% year-over-year increase, and revenue estimates at $1.02 billion, up 5.7%, indicating solid market performance.
- Historical Performance: Over the past two years, COO has beaten EPS estimates 100% of the time and revenue estimates 38% of the time, showcasing its strong ability in profitability and market expectation management, which boosts investor confidence.
- Estimate Revision Trends: In the last three months, EPS estimates have seen 10 upward revisions and 2 downward revisions, while revenue estimates experienced 2 upward and 4 downward revisions, reflecting mixed market sentiment regarding the company's future performance, which could impact stock price volatility.
- Strategic Cash Flow Target: The Cooper Companies has raised its free cash flow target to $2.2 billion by 2028, aiming to drive long-term growth through ongoing strategic reviews, thereby enhancing its competitive position in the healthcare sector.
See More
Stocks Recover Losses from Iran
- Market Reaction: The S&P 500 index has returned to its previous levels prior to the attacks in Iran.
- Impact of Events: The market's recovery indicates resilience despite geopolitical tensions.
See More
Key Companies to Monitor This Week: Jobs, CrowdStrike, Target, Broadcom, Costco, and Others
- Stock Market Performance: The S&P 500 index fell by 0.4% last week, marking a 0.9% decline for February, which is only the second monthly drop since April.
- Trading Range: The S&P 500 has been trading within a narrow range this year, with a low of approximately 6800 and a high of around 7000.
See More
Job Report Outlook Uncertain Amid Rising AI Impact
- Inflation Pressures Rise: The latest wholesale inflation report indicates that markets have underestimated pricing pressures, leading to a more than 600-point drop in the Dow Jones Industrial Average, reflecting heightened investor concerns about the economic outlook that could impact future interest rate policies.
- Job Market Expectations: The U.S. economy is expected to add 60,000 jobs in February, with the unemployment rate holding steady at 4.3%, a figure significantly lower than last month's 130,000, indicating a market acceptance of a 'no hire, no fire' phenomenon, yet fears of AI's potential threat to employment are intensifying.
- Deepening AI Impact: Block's announcement of 4,000 layoffs to leverage AI automation led to a 24% surge in its stock price, but concerns about AI's potential to disrupt the economy have escalated, particularly affecting the software and real estate sectors.
- Uncertain Rate Outlook: Mizuho's chief economist anticipates payrolls of 100,000 in February, which could influence interest rate expectations; while the market currently prices in two rate cuts, he suggests the actual outcome may be zero, posing negative implications for the stock market.
See More
Insiders Invested Heavily in These 3 Stocks in Q4—One Shines Above the Rest
Insider Buying Trends: Insider buying was prominent in Q4 2025, particularly in three stocks, with one standout due to its simple and effective technology that is in high demand in a rapidly growing industry.
Stock Performance and Institutional Activity: Insiders, including directors, have been actively purchasing shares, accumulating about 2% of the stock, while institutions own around 24%, indicating strong market interest despite a decline in stock prices.
Market Sentiment and Short Interest: Short interest remains high at nearly 7%, contributing to stock price declines, but analysts suggest a potential rebound with a significant upside forecast of 200% relative to consensus targets.
Investment Recommendations: Analysts rate the stock as a moderate buy, with a minimum upside of 12%, indicating a favorable long-term outlook as the market stabilizes and improves in revenue and earnings.
See More
Teva Pharmaceuticals' Request to Delay Paragard Lawsuit Trial Denied by Judge
- Trial Progress: A Georgia federal judge denied Teva Pharmaceuticals' request to delay the Paragard IUD lawsuit trial, ruling that it will proceed on January 20, 2024, marking the first trial in approximately 3,800 lawsuits, which could significantly impact the company's future legal liabilities and financial outlook.
- Litigation Context: Plaintiffs allege that the Paragard device can fracture during removal, leading to injuries and fertility complications, while Teva argues that FDA approval should preempt state law claims, indicating the company's urgency in its legal strategy to appeal for dismissal of the claims.
- Compliance Issues: The judge expressed concern over Teva's five-year delay in updating Paragard's warning labels as mandated by the FDA in 2010, suggesting potential intentionality that could undermine the court's trust in Teva and affect the case's outcome, thereby increasing the company's legal risks.
- Market Reaction: Teva's stock fell 0.21% to $32.72 in the latest trading session, reflecting market concerns about the upcoming trial and its potential financial implications, which may lead to decreased investor confidence.
See More
The Cooper Companies to Announce Q1 Earnings on March 5
- Earnings Announcement: The Cooper Companies (COO) is set to release its Q1 2023 earnings on March 5 after market close, with consensus EPS estimates at $1.03, reflecting a 12% year-over-year increase, and revenue estimates at $1.02 billion, up 5.7%, indicating solid market performance.
- Historical Performance: Over the past two years, COO has beaten EPS estimates 100% of the time and revenue estimates 38% of the time, showcasing its strong ability in profitability and market expectation management, which boosts investor confidence.
- Estimate Revision Trends: In the last three months, EPS estimates have seen 10 upward revisions and 2 downward revisions, while revenue estimates experienced 2 upward and 4 downward revisions, reflecting mixed market sentiment regarding the company's future performance, which could impact stock price volatility.
- Strategic Cash Flow Target: The Cooper Companies has raised its free cash flow target to $2.2 billion by 2028, aiming to drive long-term growth through ongoing strategic reviews, thereby enhancing its competitive position in the healthcare sector.
See More
Stocks Recover Losses from Iran
- Market Reaction: The S&P 500 index has returned to its previous levels prior to the attacks in Iran.
- Impact of Events: The market's recovery indicates resilience despite geopolitical tensions.
See More
Key Companies to Monitor This Week: Jobs, CrowdStrike, Target, Broadcom, Costco, and Others
- Stock Market Performance: The S&P 500 index fell by 0.4% last week, marking a 0.9% decline for February, which is only the second monthly drop since April.
- Trading Range: The S&P 500 has been trading within a narrow range this year, with a low of approximately 6800 and a high of around 7000.
See More
Job Report Outlook Uncertain Amid Rising AI Impact
- Inflation Pressures Rise: The latest wholesale inflation report indicates that markets have underestimated pricing pressures, leading to a more than 600-point drop in the Dow Jones Industrial Average, reflecting heightened investor concerns about the economic outlook that could impact future interest rate policies.
- Job Market Expectations: The U.S. economy is expected to add 60,000 jobs in February, with the unemployment rate holding steady at 4.3%, a figure significantly lower than last month's 130,000, indicating a market acceptance of a 'no hire, no fire' phenomenon, yet fears of AI's potential threat to employment are intensifying.
- Deepening AI Impact: Block's announcement of 4,000 layoffs to leverage AI automation led to a 24% surge in its stock price, but concerns about AI's potential to disrupt the economy have escalated, particularly affecting the software and real estate sectors.
- Uncertain Rate Outlook: Mizuho's chief economist anticipates payrolls of 100,000 in February, which could influence interest rate expectations; while the market currently prices in two rate cuts, he suggests the actual outcome may be zero, posing negative implications for the stock market.
See More
Insiders Invested Heavily in These 3 Stocks in Q4—One Shines Above the Rest
Insider Buying Trends: Insider buying was prominent in Q4 2025, particularly in three stocks, with one standout due to its simple and effective technology that is in high demand in a rapidly growing industry.
Stock Performance and Institutional Activity: Insiders, including directors, have been actively purchasing shares, accumulating about 2% of the stock, while institutions own around 24%, indicating strong market interest despite a decline in stock prices.
Market Sentiment and Short Interest: Short interest remains high at nearly 7%, contributing to stock price declines, but analysts suggest a potential rebound with a significant upside forecast of 200% relative to consensus targets.
Investment Recommendations: Analysts rate the stock as a moderate buy, with a minimum upside of 12%, indicating a favorable long-term outlook as the market stabilizes and improves in revenue and earnings.
See More
Teva Pharmaceuticals' Request to Delay Paragard Lawsuit Trial Denied by Judge
- Trial Progress: A Georgia federal judge denied Teva Pharmaceuticals' request to delay the Paragard IUD lawsuit trial, ruling that it will proceed on January 20, 2024, marking the first trial in approximately 3,800 lawsuits, which could significantly impact the company's future legal liabilities and financial outlook.
- Litigation Context: Plaintiffs allege that the Paragard device can fracture during removal, leading to injuries and fertility complications, while Teva argues that FDA approval should preempt state law claims, indicating the company's urgency in its legal strategy to appeal for dismissal of the claims.
- Compliance Issues: The judge expressed concern over Teva's five-year delay in updating Paragard's warning labels as mandated by the FDA in 2010, suggesting potential intentionality that could undermine the court's trust in Teva and affect the case's outcome, thereby increasing the company's legal risks.
- Market Reaction: Teva's stock fell 0.21% to $32.72 in the latest trading session, reflecting market concerns about the upcoming trial and its potential financial implications, which may lead to decreased investor confidence.
See More
